Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy [0.03%]
无scar环形mRNA递送的CAR-T细胞治疗展现优良抗肿瘤效果
Qinchao Hu,Hui Zhao,Kaicheng Zhou et al.
Qinchao Hu et al.
Messenger RNA (mRNA)-based transient expression of chimeric antigen receptors (CARs) results in optimal safety profiles and provides promising opportunities to address existing challenges associated with viral vector-based CAR-T-cell therap...
Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis [0.03%]
溶瘤腺病毒递送新抗原可使低突变肿瘤对anti-PD-1治疗敏感并预防转移
Ke-Yu Shen,Shi-Zhe Yu,Ying-Han Su et al.
Ke-Yu Shen et al.
Neoantigen vaccines and oncolytic viruses are emerging immunotherapies that can reshape the tumor microenvironment (TME). However, tumors with low mutation burdens often respond poorly to immunotherapies because of their limited immunogenic...
Working together: a multi-component intranasal vaccine provides synergistic protection against COVID-19 [0.03%]
联合行动：多组分鼻内疫苗在预防新冠肺炎方面具有协同作用
Jessica A Breznik,Chris P Verschoor
Jessica A Breznik
YTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer [0.03%]
YTHDF1通过抑制NOTCH1诱导的肿瘤干细胞特性来调控结直肠癌化疗效果
Henley Cheung,Huarong Chen,Danyu Chen et al.
Henley Cheung et al.
N6-methyladenosine (m6A) modification of mRNAs is a predominant epigenetic regulatory mechanism in tumor initiation and progression. Cancer stem cells (CSCs) are the key drivers of colorectal cancer (CRC) initiation and chemotherapy resista...
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma [0.03%]
SHR-1701联合白蛋白结合型紫杉醇和吉西他滨治疗晚期胰腺导管腺癌 Ib/II 期临床研究
Ran Xue,Miaoyan Wei,Jiajia Yuan et al.
Ran Xue et al.
Nab-paclitaxel plus gemcitabine (AG) is the standard first-line chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma and has limited efficacy. This phase 1b/2 study aimed to evaluate SHR-1701 (an anti-PD-L1/TGF-βRII fus...
Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk [0.03%]
针对BCMA的CAR-T细胞可减轻进行性多发性硬化的微胶质细胞活化：提示浆细胞-微胶质细胞串扰
Fatme S Ismail,Hans-Peter Hartung,Nico Melzer
Fatme S Ismail
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers [0.03%]
缺氧诱导的VEGF分泌促进双特异性T细胞衔接子的抗性
Mengyao Xu,Syem K Barakzai,Raj Kumar et al.
Mengyao Xu et al.
Bispecific T-cell Engagers (BITEs) are a novel form of immunotherapy that overcome a deficiency of immune checkpoint inhibitors (ICI) by targeting a preidentified tumor associated antigen and redirecting a polyclonal population of effector ...
Repartitioning brain glucose: serine-nucleotide dependency sensitizes glioblastoma therapy [0.03%]
脑葡萄糖重新分布：依赖.serine-核苷酸的敏感性胶质母细胞瘤疗法
Yanggang Hong,Chunyan Hua,Min Wu
Yanggang Hong
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial [0.03%]
新型CDK2/4/6抑制剂曲拉西利(TQB3616)联合氟维司群治疗既往经治的激素受体阳性、HER2阴性晚期乳腺癌患者：一项随机、双盲、多中心III期临床试验
Yongmei Yin,Qingyuan Zhang,Tao Sun et al.
Yongmei Yin et al.
CDK2 is a principal mediator of CDK4/6 resistance. Concurrent CDK2/4/6 blockade may be effective in treating HR-positive, HER2-negative advanced breast cancer (ABC). This randomized, double-blind, parallel-controlled, phase 3 trial (Clinica...
Hypoglycemia induces brain metabolic reprogramming and neurodegeneration via serum response factor and myocardin-related transcription factor-A [0.03%]
低血糖通过血清反应因子和肌球蛋白相关转录因子A诱导大脑代谢重构和神经退行性病变
Minjeong Jang,Hyung Jin Choi,Hae-June Lee et al.
Minjeong Jang et al.
Hypoglycemia is a frequent and potentially severe complication that can result in significant brain injury in individuals with diabetes treated with insulin or other hypoglycemic agents and in those undergoing prolonged fasting. Despite its...